<code id='93841C04FD'></code><style id='93841C04FD'></style>
    • <acronym id='93841C04FD'></acronym>
      <center id='93841C04FD'><center id='93841C04FD'><tfoot id='93841C04FD'></tfoot></center><abbr id='93841C04FD'><dir id='93841C04FD'><tfoot id='93841C04FD'></tfoot><noframes id='93841C04FD'>

    • <optgroup id='93841C04FD'><strike id='93841C04FD'><sup id='93841C04FD'></sup></strike><code id='93841C04FD'></code></optgroup>
        1. <b id='93841C04FD'><label id='93841C04FD'><select id='93841C04FD'><dt id='93841C04FD'><span id='93841C04FD'></span></dt></select></label></b><u id='93841C04FD'></u>
          <i id='93841C04FD'><strike id='93841C04FD'><tt id='93841C04FD'><pre id='93841C04FD'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:4595
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Lack of darker skin in textbooks, journals harms patients of color
          Lack of darker skin in textbooks, journals harms patients of color

          HyacinthEmpinado/STATWhendermatologistJennaLesterlearnedthatrashesonskinandtoeswereasymptomofCovid-1

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Average age of first period drops to 11.9 years, study shows

          AdobeMenstruationisacriticalindicatorofhealth.Whetherandwhensomeonewithauterusgetstheirperiod—forthe